Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Targeted cancer therapies

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Market for targeted cancer therapies.


  1. IMS Health. Press release (1 April). IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $300.3 billion. IMS Health website [online], (2010).

  2. Kerbel, R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171–1175 (2006).

    Article  CAS  Google Scholar 

  3. Sawyers, C. L. Cancer: mixing cocktails. Nature 449, 993–996 (2007).

    Article  CAS  Google Scholar 

  4. Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).

    Article  CAS  Google Scholar 

  5. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  Google Scholar 

  6. Storey, S. Chronic myelogenous leukaemia market. Nature Rev. Drug Discov. 8, 447–448 (2009).

    Article  CAS  Google Scholar 

  7. Bach, P. B. Limits on Medicare's ability to control rising spending on cancer drugs. N. Engl. J. Med. 360, 626–633 (2009).

    Article  CAS  Google Scholar 

  8. WHO. Cancer. WHO website [online], (2010).

  9. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Approved targeted cancer therapies (PDF 69 kb)

Supplementary information S2 (table)

Expansion of indications for imatinib: US FDA approvals (PDF 61 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aggarwal, S. Targeted cancer therapies. Nat Rev Drug Discov 9, 427–428 (2010).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing